AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04890392
Drug: PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1: 40\~60mg Bid，d1\~14, q3w. Oxaliplatin：130mg/m2，iv drip for 2h，d1, q3w. PD-1（Tislelizumab）:200mg,iv drip for at least 1h,d1,q3w. Stage I: PD1 inhibitor + SOX regimen (q3W) . Stage II: PD1 inhibitor + SOX regimen (q3W) Stage III: PD1 inhibitor + SOX regimen (q3W) . Efficacy evaluation,then followed by surgery.
Trial: NCT05543785
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 30 mg ketorolac tromethamine diluted in normal saline in a total volume of 50 ml will be injected
Trial: NCT05545670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: not containing drugs
Trial: NCT05951712
Drug: N Acetyl cysteine 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impact of N Acetyl cysteine on the mucosal visibility of stomach and duodenum
Trial: NCT05951712
Drug: Simethicone 150mg plus N Acetyl cysteine 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impact of simethicone plus N Acetyl cysteine on the mucosal visibility of stomach and duodenum
Trial: NCT05114603
Drug: HLX208
FDA approved: no
EMA approved: no
PMDA approved: no
Description: level 1:600mg po Bid level 2:900mg po Bid
Trial: NCT04989049
Drug: Folic Acid 5 MG
RxNorm normalized name: folic acid 5 MG
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: folic acid tablet of 5mg will be placed on the ulcers 2 times per day for 7 days
Trial: NCT00002275
Drug: Fat Emulsion 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002275
Drug: Fat Emulsion 20%
RxNorm normalized name: Fat Emulsion 20% Intravenous Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06414499
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical care according to the guideline (Stroke. 2019;50(12): e344-e418.). Antiplatelet therapy is chosen by researchers-Single/dual antiplatelet therapy can be chosen.
Trial: NCT00000984
Drug: CD4 Antigens
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05378074
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
Trial: NCT06164873
Drug: IBI362
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly injections of gradually increased doses of IBI362
Trial: NCT06164873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly injections of volume-matched placebo
Trial: NCT05097794
Drug: BR1015-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Administration to the BR1015-1 group: 60 mg of BR1015-1 will be administered one tablet once a day, five-day repeated doses.
Trial: NCT05097794
Drug: BR1015-1 + BR1015-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Co-administration to the BR1015-1+BR1015-2 group: 60 mg of BR1015-1 one tablet and 1.5 mg of BR1015-2 one tablet will be co-administered once a day, five-day repeated doses.
Trial: NCT05559125
Drug: STSA-1002 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT05559125
Drug: STSA-1005 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT05920408
Drug: EXS21546
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EXS21546 Granule in Capsule
Trial: NCT04570293
Drug: vehicle plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle patches are identical to the active patch, except for the absence of lidocaine, without any optical differences.For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
Trial: NCT04838704
Drug: Ruxolitinib+Calcineurin +Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low-dose ruxolitinib combine with calcineurin and short course of methotrexate.
Trial: NCT04838704
Drug: Calcineurin +Methotrexate+Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: calcineurin and short course of methotrexate and mycophenolate mofetil
Trial: NCT04932291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule
Trial: NCT05623111
Drug: Incobotulinumtoxin-A 100 UNIT Injection
RxNorm normalized name: incobotulinumtoxinA 100 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perineural injection
Trial: NCT05977166
Drug: medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
Trial: NCT04276155
Drug: non-systematic prescription of anticoagulant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the prescription of anticoagulant is managed by an implantable device follow up
Trial: NCT04512638
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment is the same in all groups.~Monotherapy for 4 weeks with:~No penicillin contra-indication~* Amoxicillin-clavulanate 875mg tid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~After 4 weeks patients will be switched to consolidation antibiotics:~No penicillin contra-indication~* Amoxicillin 1g bid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~Antibiotic treatment can be discontinued after 4 weeks when the MRONJ lesions has healed.
Trial: NCT03063190
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive placebo oral tablets
Trial: NCT05514249
Drug: CRD-TMH-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive a single dose of CRD-TMH-001 administered via intravenous injection.
Trial: NCT05450627
Drug: Pancreatic Enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Registry of pancreatic enzyme therapy prescribed to included patients
Trial: NCT05699070
Drug: DWC202211 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWC202211 for 5 days~Aspirin 100mg
Trial: NCT05699070
Drug: DWC202212 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWC202212 for 3 days~Rabeprazole 5mg
Trial: NCT05699070
Drug: DWC202211 100mg + DWC202212 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWC202211 + DWC202212 for 5 days~Aspirin 100mg, Rabeprazole 5mg
Trial: NCT05042609
Drug: FDA approved steroid eye drop (masked)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA approved steroid eye drop Dosed four times a day (QID)
Trial: NCT06184958
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C:placebo group (25 patients) will receive placebo 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks
Trial: NCT05293678
Drug: REGN15160 (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered in single intravenous (IV) dose
Trial: NCT05293678
Drug: Matching Placebo (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered in single IV dose
Trial: NCT05293678
Drug: REGN15160 (SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered in single subcutaneous (SC) dose
Trial: NCT05293678
Drug: Matching Placebo (SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered in single SC dose
Trial: NCT04574947
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.
Trial: NCT05549154
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo was filled with excipients (aniseed ether, refined vegetable oil), and the shape and size were the same as vitamin D2 soft capsule.the control group was given placebo, 5 placebo capsules twice weekly for 6 months of the intervention. The medication was dispensed by a designated person (not the investigator) in advance and independently according to the patient's medication number (only the drug number was provided on the outer packaging).
Trial: NCT05608785
Drug: IBI315
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI315 is a recombinant fully humanized anti-programmed death receptor 1 (PD-1) and humanized anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody injection.
Trial: NCT05608785
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
Trial: NCT05608785
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Trial: NCT05608785
Drug: Anrotinib
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling.
Trial: NCT05493267
Drug: Treatment regimens for MDR-TB
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
Trial: NCT05525182
Drug: ES16001 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composition: Elaeocarpus extract 40mg tablet
Trial: NCT05525182
Drug: ES16001 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elaeocarpus extract 80 mg tablet
Trial: NCT05525182
Drug: ES16001 160 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elaeocarpus extract 160 mg tablet
Trial: NCT05525182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablet: Tablets for oral use indistinguishable from ES16001 in size, appearance, taste and smell
Trial: NCT04857827
Drug: QLS-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
Trial: NCT05749393
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous heparin was administered during intracranial aneurysm embolization with a guide catheter and discontinued at the end of the procedure.
Trial: NCT05233410
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Trial: NCT06256991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a powder with a similar appearance, smell, and taste as patiromer, but without and clinically detectable effects. It is intended for oral intake.
Trial: NCT05320393
Drug: PrabotulinumtoxinA-Xvfs
RxNorm normalized name: prabotulinumtoxinA-xvfs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One treatment of 40 units
Trial: NCT05320393
Drug: PrabotulinumtoxinA-Xvfs
RxNorm normalized name: prabotulinumtoxinA-xvfs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One treatment of 20 units
Trial: NCT04835168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04759365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo formulation for oral capsule
Trial: NCT06408116
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemotherapy
Trial: NCT05660135
Drug: Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/5mg Olomax Tab 40/5/10mg
Trial: NCT00002085
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05559307
Drug: Xingnaojing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xingnaojing injection 20 ml+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 7 days.
Trial: NCT04991480
Drug: ART4215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ART4215 by mouth daily in 21-day cycles.
Trial: NCT04957758
Drug: OC-01 (varenicline) nasal spray 1.2 mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-01
Trial: NCT04957758
Drug: Placebo (vehicle) nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle)
Trial: NCT05680558
Drug: UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracorporeal Photopheresis (ECP)
Trial: NCT05848765
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anthracycline
Trial: NCT05926427
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not specified, recommended regimen according to histopathologic type
Trial: NCT05848765
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alkylating agent (chemotherapy drug)
Trial: NCT05848765
Drug: Investigation agent 2
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug used in round 2 is yet to be confirmed, round 2 is estimated to open in Q4 2025 and the record will be updated when the drug has been confirmed
Trial: NCT05848765
Drug: Investigation agent 3
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug used in round 3 is yet to be confirmed, round 3 is estimated to open in Q3 2027 and the record will be updated when the drug has been confirmed
Trial: NCT00002363
Drug: Peptide Construction 3, Synthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05674253
Drug: Dexmedetomidine + Hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive dexmedetomidine 0.7 ɥg/kg/hr IV infusion before aortic cross-clamping, and will be continued intra-operatively and in ICU till weaning from mechanical ventilation Patients also will also receive Hydrocortisone 100 mg intravenous (IV) before aortic cross-clamping then 100 mg every 8 hours after surgery which will be continued for 48 hours
Trial: NCT04687423
Drug: FCN-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-011 will be given orally in ascending doses starting at 50 mg Q12h or 100mg QD until the maximum tolerated dose or recommended dose is reached.
Trial: NCT04485260
Drug: KRT-232
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered by mouth
Trial: NCT05444257
Drug: VX-121/TEZ/D-IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablets for oral administration.
Trial: NCT06104956
Drug: HFNO weaning protocol
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm based on SpO2 values and respiratory rate: a decrease of FiO2 and of the flow will be done
Trial: NCT06104956
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weaning methods will be left to the free choice of the practitioner.
Trial: NCT04762498
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg oral dose methotrexate administered weekly
Trial: NCT04512911
Drug: Antiarrhythmic medications
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of anti arrhythmic medication or dose increase
Trial: NCT04733963
Drug: Fruquintinib Plus Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
Trial: NCT05568550
Drug: Androgen Deprivation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen Deprivation Therapy (either LHRH agonist or LHRH antagonist) as per treating physician choice will be allowed within 3 months prior to randomization. Duration is per institutional standards.
Trial: NCT05441956
Drug: TGRX-326
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are given TGRX-326 tablets orally at one of the dose levels as pre-determined.
Trial: NCT03033472
Drug: 600 mg Clindamycin orally
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg Clindamycin orally 30 minutes before treatment
Trial: NCT03033472
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo 30 minutes before treatment
Trial: NCT05682859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT05168995
Drug: BDP/FF NEXThaler® 100/6 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF NEXThaler® 100/6 maintenance treatment: one or two inhalations twice daily (one inhalation in the morning and one inhalation in the evening).~BDP/FF NEXThaler® 100/6 maintenance and reliever treatment (MART)
Trial: NCT05536856
Drug: a new effervescent mixture 5-florouracil formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 patients will apply a new effervescent mixture 5-florouracil formula prepared at faculty of pharmacy (Girls) - Al-Azhar university
Trial: NCT05536856
Drug: 5-Fluorouracil plain powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 patients will apply the 5-florouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder
Trial: NCT05518708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05251038
Drug: 5 Fluorouracil (5FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per standard of care
Trial: NCT05251038
Drug: Leucovorin (LV)
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Per standard of care
Trial: NCT05345210
Drug: Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)
RxNorm normalized name: AMOXICILLIN/CLARITHROMYCIN/VONOPRAZAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
Trial: NCT05345210
Drug: Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
Trial: NCT05345210
Drug: Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days
Trial: NCT05562349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule with no active medication - identical to drug capsule
Trial: NCT06194500
Drug: [14C]-LY3549492
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as oral solution.
Trial: NCT06194500
Drug: LY3549492
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06194500
Drug: [14C]-LY3549492
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as IV infusion.
Trial: NCT00967759
Drug: Fenilefrine isolated
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution: Fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
Trial: NCT05693454
Drug: Infiltration with Ropivacain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local wound infiltration at the end of spine surgery with Ropivacain
Trial: NCT00771121
Drug: urea/lactic acid
RxNorm normalized name: urea/lactic acid/propylene gly TOPICAL SOLUTION, NON-ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: new emulsion type
Trial: NCT00771121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: only emulsion base